Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Biomedtracker: follow the drug development process

Track and assess key events that will impact a drug’s probability of technical success and approval.

Key benefits:

Stay up to date
Get ahead of the competition
Conference coverage

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Generics Bulletin

A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.

Key benefits:

Ask-the-Analyst™ Service
A powerful online platform
In-depth content coverage

View all content

Scrip

India Lockdown Early Signs of Manufacturing Strains But Resolutions Underway

Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’

Topic Coronavirus

View article
Scrip

Tech Transfer Roundup: Universities And Biotechs Continue To Look For Ways To Combat COVID-19

AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.

Topic Coronavirus Medtech

View article
Scrip

Coronavirus Update: South Korea's Celltrion Progresses Antibody, Yancopoulos: 'The World Is Counting On Us'

Regeneron's head of R&D George Yancopoulos delivers some stirring words about the need to unify against the global threat posed by COVID-19.

Topic Coronavirus

View article
Scrip

Experts Say COVID-19 Battle Needs More Funding, Cooperation

Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.

Topic Coronavirus

View article
Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet...

COVID-19 Infographic

Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

Topic Coronavirus

View infographic
Biomedtracker

Biomedtracker Potential Pivots in 2020

In this infographic, we provide insight into key trials that are expecting developments in the approval process.

View infographic
Generics Bulletin

Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

Topic Coronavirus

View article
In Vivo, HBW Insight, Pink Sheet, Scrip, Generics Bulletin, ...

Coronavirus: Keep up to date with Breaking News and Insight

Track the latest developments in the worldwide coronavirus outbreak and what it means for the pharma, medtech, generics and OTC industries with coverage from the Informa Pharma Intelligence Insights suite of tools. Get vital breaking news and penetrating analysis about the impact of this global health crisis.

Topic Coronavirus

Single report
Generics Bulletin

Preserving Full Capacity Is Key To Global Coronavirus Reponse

Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.

Topic Coronavirus

View article
Generics Bulletin

Celltrion Pledges Efforts on Coronavirus Antibody And Kit

Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.

Topic Coronavirus

View article
HBW Insight

EU Coronavirus Situation 'Evolving Very Rapidly' Says AESGP

In response to the outbreak of the Covid-19 pandemic in Europe, the region's self-care industry is working hard to keep shelves stocked with crucial OTC medicines and food supplements, according to the AESGP.

Topic Coronavirus

View article
Generics Bulletin

Green Lanes Will Help EU Fight Coronavirus

Industry has welcomed the European Commission’s introduction of priority freight lanes, or ‘green lanes’, for essential goods to help address the challenges posed by the coronavirus outbreak.

Topic Coronavirus

View article
Scrip

Some Caution Over 'People’s Hope' Remdesivir As China Trials Progress

Although Gilead’s remdesivir shows promise against the coronavirus, efficacy is not guaranteed, one antiviral company executive tells Scrip, as multiple other potential therapies and vaccines move forward.

Topic Coronavirus

View article
Scrip

Bad For Pharma: Sales Reps And Patients Are Staying Home

Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.

Topic Coronavirus

View article
HBW Insight

Covid-19 Disrupting Supply Chains Short-Term, Could Spark Long-Term Procurement Shifts

UNPA anticipates supplies of a ‘significant number’ of China-sourced supplement ingredients will be ‘critical’ by late April as Covid-19 disrupts shipments. During a recent webinar, UNPA CEO Loren Israelsen said he expects disruptions to continue until at least mid-year.

View article